Publication of clinical trial results
The information given below and the relevant links to the clinical data fulfil the requirements of articles 71-73 of the ordinance on medicinal products (MPO). They supplement the information published in association with the Swiss marketing authorisation for the medicinal product.
Rybrevant®, concentrate for solution for infusion
Authorization study:
61186372EDI1001
Carvykti®
Authorisation study:
68284528MMY2001
Tecvayli®, solution for injection
Authorisation study:
64007957MMY1001
Talvey®, solution for injection
Authorisation study:
64407564MMY1001
Balversa®, film-coated tablets
Authorisation study:
42756493BLC3001
Lazcluze®, film-coated tablets
Authorisation study:
73841937NSC3003
Imaavy®, concentrate for solution for infusion
Autorisation studies:
MOM-M281-011
80202135MYG2001
The publications listed above cover trials relevant to the Swiss marketing authorisation. Results from all Johnson & Johnson clinical trials conducted globally are available on our international clinical trial results platform.